$-27.52
(Market cap
$35 Mln
Recently Viewed
Clear AllMarket cap
$35 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-1 Mln
ROE
-0.2 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-1.4
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
1,208,930
CFO
$-107.86 Mln
EBITDA
$-116.09 Mln
Net Profit
$-113.06 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
ARCA Biopharma Inc (ABIO)
| -87.8 | -93.3 | -94.0 | -90.0 | -59.2 | -48.5 | -49.1 |
|
BSE Sensex*
| -7.9 | 6.3 | -6.4 | -3.5 | 8.5 | 9.9 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
ARCA Biopharma Inc (ABIO)
| -28.3 | 10.2 | -46.4 | -29.8 | -4.9 | -75.1 | -52.6 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
ARCA Biopharma Inc (ABIO)
|
2.5 | 34.8 | 0.2 | -7.2 | -4,994.9 | -20.7 | -- | 1.1 |
| 1.5 | 10.4 | 21.6 | -15.9 | -33.5 | -- | -- | 1.8 |
ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted... beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado. Read more
Co-Founder, President, CEO & Director
Dr. Michael R. Bristow M.D., Ph.D.
Co-Founder, President, CEO & Director
Dr. Michael R. Bristow M.D., Ph.D.
Headquarters
Westminster, CO
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of ARCA Biopharma Inc (ABIO) is $2.48 (NASDAQ) as of 30-Aug-2024 19:22 EDT. ARCA Biopharma Inc (ABIO) has given a return of -59.23% in the last 3 years.
Since, TTM earnings of ARCA Biopharma Inc (ABIO) is negative, P/E ratio is not available.
The P/B ratio of ARCA Biopharma Inc (ABIO) is 1.07 times as on 06-Sep-2024, a 75 discount to its peers’ median range of 4.29 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
The 52-week high and low of ARCA Biopharma Inc (ABIO) are Rs -- and Rs -- as of 06-May-2026.
ARCA Biopharma Inc (ABIO) has a market capitalisation of $ 35 Mln as on 06-Sep-2024. As per SEBI classification, it is a Small Cap company.
Before investing in ARCA Biopharma Inc (ABIO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.